CryoHoldco has announced the acquisition of Criocord, a cord blood bank and cell therapy institute in Perù, for an undisclosed sum. CryoHoldco already owns the cord blood market leaders in Mexico and Colombia and now controls an important asset in Peru. A portfolio company of ACON investments, CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the largest cord blood banks worldwide. [Read more…]
On June 4, 2018, Cryo–Cell International, announced it is acquiring the hybrid public-private cord blood bank CORD:USE for $14 million.
Terms of the Cryo-Cell International and CORD:USE Deal
To acquire substantially all of the assets of Cord:Use Cord Blood Bank, Cryo-Cell is paying $14 million, split between $10.5 million in cash and the issuance of 470K shares of Cryo-Cell stock. [Read more…]
After a rapid growth period through the mid-2000s, the global cord blood banking market reached saturation and stabilized through approximately 2012. Since that time, the market has been aggressively consolidating.
In this article:
- Cord Blood Industry Consolidation in U.S.
- Cord Blood Industry Consolidation in Europe
- Cord Blood Industry Consolidation in Asia
- Cord Blood Industry Consolidation in Latin America
- Cord Blood Industry Consolidation in India
- Trend of Cord Blood Industry Consolidation
Cord tissue banking is the processing and storage of a newborn’s umbilical cord tissue or the components contains, such as Wharton’s jelly. Wharton’s jelly is a thick, gelatinous substance present within the human umbilical cord that contains a range of important cell types, such as mesenchymal stem cells (MSCs), fibroblasts and macrophages.
Cord Tissue Banking and Its Benefits
In this article:
With the global cord blood banking industry maturing and consolidating over the past five years, it is more important than ever to be well-educated about cord blood industry trends. There are now fewer market players, because numerous small cord blood banks have either been acquired or gone out of business.
However, this era of maturation and consolidation has had as many benefits to surviving cord blood banks as drawbacks. On average, the remaining market participants are now larger, stronger, better capitalized, and storing larger quantities of cord blood and tissue units than when the market was more fragmented.